Researchers at the Technion’s Ruth and Bruce Rappaport Faculty of Medicine and the Rappaport Family Institute for Research in the Medical Sciences have discovered a subset of blood cells that predict the success of immunotherapy treatment. These findings are expected to streamline the process of matching an immunotherapy treatment to a specific patient, since it is very important to identify in advance those patients who will react to a given treatment. The research published in Cancer Cell was led by doctoral student Madeleine Benguigui and post-doctoral fellow Dr. Tim J. Cooper, under the supervision of Professor Yuval Shaked of the Rappaport Faculty of Medicine. They contributed equally to the research and to the article. The translational research is based on RNA sequencing (scRNA-seq), analysis of existing data, pre-clinical models of cancer, and the corroboration of the findings in humans.
Background
Immunotherapy, which is considered one of the most important breakthroughs in the treatment of cancer, is based on the understanding that the natural immune system excels at attacking cancer cells in a selective and precise manner. The problem is that, in many cases, the cancerous tumor tricks the immune system and prevents it from identifying the cells as enemies. Immunotherapy is based on the concept that, instead of attacking the cancer with chemotherapy drugs that also harm healthy tissue, it is preferable to boost the immune system with the goal to identify cancer cells as enemies and let it do the rest of the work on its own.
Despite the remarkable success of the immunotherapy approach for treating cancer, its effectiveness is still limited to around 40% of all patients. This means that many patients receive this harsh treatment without positive results. Consequently, it is crucial to attain a deep understanding of biological reactions to these treatments and to identify biomarkers that can predict the treatment’s future success.
Biomarkers are an important component of personalized medicine, which help physicians make educated medical decisions and formulate optimal treatment protocols adapted to the specific patient and their medical profile. Biomarkers are already being used for immunotherapy treatments, but they are obtained through biopsies – an invasive procedure that can endanger the patient. Moreover, this approach fails to sufficiently take into account the specific patient’s immune profile and its predictive capability is limited. For this reason, a great deal of research in this field – both in industry and in academia – strives to find new ways to predict which patients will respond to immunotherapy treatments.
Technion researchers who focused on antibody-based immunotherapy discovered biomarkers that predict a specific patient’s response to the treatment. Since these biomarkers are in the bloodstream, they don’t require taking biopsies from the tumor – an invasive procedure that is not always feasible and, as mentioned, can sometimes endanger the patient. In brief, the researchers discovered that a protein called STING, that activates the immune system, is triggered by cancerous growths, and is especially pronounced in cancer cells that will respond to immunotherapy treatment. This protein is manifested in interferon protein, which in turn stimulates neutrophils to be differentiated to a specific type (which expresses the protein Ly6Ehi). These neutrophils act directly on the immune system and stimulate it to target the cancerous tumor. Indeed, the researchers discovered that, these neutrophils may help the actual treatment, as their presence in the tumor prompts greater sensitivity to immunotherapy treatment.
The researchers inferred that testing the levels of Ly6Ehi neutrophils in the patient’s blood could serve as an efficient biomarker for predicting the response to immunotherapy treatment. The researchers tested these findings, which were based on pre-clinical studies, on patients with lung cancer and melanoma. These findings are consistent with the analysis of existing data on 1,237 cancer patients who underwent antibody-based immunotherapy treatments. Therefore, they demonstrated the neutrophils’ ability to predict with a high degree of precision, response to immunotherapy in humans.
The technology developed by Prof. Yuval Shaked’s research group was registered as a patent and it is currently in the midst of a tech transfer process with the company OncoHost, in order to continue its development. Prof. Shaked points out that the technology can be used with the ubiquitous flow cytometry device, which can be found in almost every hospital and is approved by the regulatory agencies.
Various research groups from Israel and around the world took part in the research, including physicians and researchers from the Hadassah, Rambam, and Sheba Medical Centers, as well as from the University of Haifa, Heidelberg University (Germany), and Yale University (USA).
The research was supported by a European Research Council (ERC) grant, the Bruce & Ruth Rappaport Cancer Research Center, Israel Science Foundation, National Institutes of Health (USA), Ariane de Rothschild Foundation (Ariane de Rothschild Women’s Doctoral Program scholarship), and the Rappaport Technion Integrated Cancer Center (RTICC) as part of the Steven & Beverly Rubenstein Charitable Foundation Fellowship Fund for Cancer Research.
Click here for the paper in Cancer Cell
Click here for photos
Captions:
- Photo, from left: Prof. Yuval Shaked, Madeleine Benguigui and Dr. Tim J. Cooper:
- Prof. Yuval Shaked
- Graph, from left: The testing process up to the decision if immunotherapy treatment is suitable for the patient
Credit: Technion Spokesperson Office
For more information: Doron Shaham, Technion spokesperson – 050-3109088